Biovitrum strengthens its relationship with Wyeth
Starts to co-promote BeneFIX in the Nordic countries
10-Aug-2007 -
Biovitrum announced it has entered into a new agreement, effective August 8, 2007, with Wyeth to
co-promote BeneFIX®, Coagulation Factor IX (Recombinant) for hemophilia B, in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With the exception of these countries, Wyeth markets ...
Biovitrum
blood coagulation
Denmark
+6